It is also well established that treatment with anti-PD-1/anti-CTLA-4 combination in the 1L setting in the BRAF-mutated melanoma patients results in better outcomes when compared to the use of targeted therapy, as demonstrated in the SECOMBIT and DREAMseq trials [26,27]. The gene discussed is CTLA4; the disease is melanoma.